

# UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2011

## AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,  
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 30.06.2011 (Unaudited)	Quarter ended 30.06.2010 (Unaudited)	Half year ended 30.06.2011 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
<b>1 (a) Net Sales</b>	3,028	2,715	5,791	5,229	10,850
<b>(b) Other Operating income</b>	221	190	426	359	746
<b>Total</b>	<b>3,249</b>	<b>2,905</b>	<b>6,217</b>	<b>5,588</b>	<b>11,596</b>
<b>2 Expenditure</b>					
<b>(a) (Increase)/Decrease in stock in trade and work in progress</b>	(299)	160	(366)	170	(149)
<b>(b) Consumption of raw materials</b>	1,315	808	2,507	1,645	4,484
<b>(c) Purchase of traded goods</b>	490	400	726	814	1,055
<b>(d) Employee cost</b>	441	408	846	784	1,633
<b>(e) Depreciation</b>	54	47	108	90	197

Particulars	Quarter ended 30.06.2011 (Unaudited)	Quarter ended 30.06.2010 (Unaudited)	Half year ended 30.06.2011 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
<b>(f) Other expenditure</b>	653	504	1,215	1,017	2,396
<b>(g) Total</b>	2,654	2,327	5,036	4,520	9,616
<b>3 Profit from Operations before Other Income and Interest (1-2)</b>	595	578	1,181	1,068	1,980
<b>4 Other Income</b>	140	63	312	120	389
<b>5 Profit before Interest (3+4)</b>	735	641	1,493	1,188	2,369
<b>6 Interest</b>	-	-	-	-	29
<b>7 Profit before tax and Exceptional items (5-6)</b>	735	641	1,493	1,188	2,340
<b>8 Tax Expense</b>	238	217	490	403	790
<b>9 Net Profit for the period before Exceptional items (7-8)</b>	497	424	1,003	785	1,550
<b>10 Exceptional item (net of tax)</b>	-	-	-	-	757
<b>11 Net Profit for the period after Exceptional items (9+10)</b>	497	424	1,003	785	2,307

Particulars	Quarter ended 30.06.2011 (Unaudited)	Quarter ended 30.06.2010 (Unaudited)	Half year ended 30.06.2011 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
<b>12 Paid-up equity share capital (Face Value of Rs. 10 per Share)</b>	230	230	230	230	230
<b>13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	-	-	9,748
<b>14 Earnings Per Share (EPS) before Exceptional items (Rs.) (Basic and diluted EPS for the period and for the previous year) (Not Annualised)</b>	21.61	18.43	43.61	34.13	67.39
<b>15 Earnings Per Share (EPS) after Exceptional items (Rs.) (Basic and diluted EPS for the period and for the previous year) (Not Annualised)</b>	21.61	18.43	43.61	34.13	100.30

Particulars	Quarter ended 30.06.2011 (Unaudited)	Quarter ended 30.06.2010 (Unaudited)	Half year ended 30.06.2011 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
<b>16 Public Shareholding</b>					
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%	39.60%
<b>17 Promoters and Promoter group Shareholding</b>					
<b>a) Pledged/Encumbered</b>					
- Number of shares	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	NIL	NIL
<b>b) Non-encumbered</b>					
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total)	100.00%	100.00%	100.00%	100.00%	100.00%

Particulars	Quarter ended 30.06.2011 (Unaudited)	Quarter ended 30.06.2010 (Unaudited)	Half year ended 30.06.2011 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Year ended 31.12.2010 (Audited)
<b>shareholding of promoter and promoter group)</b>					
<b>- Percentage of shares (as a % of total share capital of the company)</b>	60.40%	60.40%	60.40%	60.40%	60.40%

**The Statement of Assets and Liabilities as required under clause 41(V)(h) of the Listing Agreement is as under:**  
(Rs. Million)

Particulars	As at June 30, 2011 (Unaudited)	As at June 30, 2010 (Unaudited)	As at December 31, 2010 (Audited)
<b>Shareholders' Funds:</b>			
<b>a) Share capital:</b>	230	230	230
<b>b) Reserves and Surplus*</b>	10,807	9,762	9,912
<b>TOTAL</b>	11,037	9,992	10,142
<b>Fixed Assets (Including Capital Work in Progress)</b>	1,978	1,765	1,844
<b>Investments</b>	4	53	4
<b>Deferred Tax Assets (Net)</b>	74	157	99
<b>Current assets, loans and advances</b>			
<b>a) Inventories</b>	2,812	2,320	2,413
<b>b) Sundry Debtors</b>	749	633	604

Particulars	As at June 30, 2011 (Unaudited)	As at June 30, 2010 (Unaudited)	As at December 31, 2010 (Audited)
<b>c) Cash and Bank Balances</b>	5,138	5,799	6,554
<b>d) Loans and Advances</b>	2,955	1,535	2,567
<b>Less: Current Liabilities and Provisions</b>			
<b>a) Liabilities</b>	1,798	1,447	1,737
<b>b) Provisions*</b>	875	822	2,206
<b>TOTAL</b>	<b>11,037</b>	<b>9,992</b>	<b>10,142</b>

\*After considering Interim Dividend.

### Notes:

- The above results were approved by the Board of Directors of the Company at its Meeting held on July 28, 2011.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended June 30, 2011.
- The Board of Directors has declared an Interim Dividend of Rs. 4 per Equity share of Rs 10 to be paid to those Members whose names appear on the Register of Members of the Company on August 4, 2011 being the Record Date. The said dividend will be paid on August 18, 2011.
- The break up of Net Sales is as follows:

(Rs. Million)

	Quarter ended June 30, 2011	Quarter ended June 30, 2010	Growth %	Half Year ended June 30, 2011	Half Year ended June 30, 2010	Growth %
<b>Domestic Sales-Others</b>	2,440	2,177	12.1%	4,661	4,150	12.3%
<b>Export Sales</b>	588	538	9.3%	1,130	1,079	4.7%
<b>Total sales</b>	<b>3,028</b>	<b>2,715</b>	<b>11.5%</b>	<b>5,791</b>	<b>5,229</b>	<b>10.7%</b>

- The Company has a single business segment namely 'Pharmaceutical Business'.
- Information on investor complaints is furnished below:

Pending as on April 1, 2011	Received during the quarter	Disposed of during the quarter	Pending as on June 30, 2011
Nil	14	14	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

**AVENTIS PHARMA LIMITED**  
**DR. SHAILESH AYYANGAR**  
**MANAGING DIRECTOR**